ARVINAS INC. - COMMON STOCK

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

10 12 2024 08:05:00 提供 Nasdaq GlobeNewswire

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

27 11 2024 06:00:31 提供 Nasdaq GlobeNewswire

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

25 11 2024 16:35:18 提供 Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 11 2024 06:00:13 提供 Nasdaq GlobeNewswire

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

30 10 2024 06:00:45 提供 Nasdaq GlobeNewswire

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

22 10 2024 15:05:06 提供 Nasdaq GlobeNewswire

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

21 10 2024 06:00:00 提供 Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

29 8 2024 06:00:48 提供 Nasdaq GlobeNewswire

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

30 7 2024 06:00:00 提供 Nasdaq GlobeNewswire

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

24 6 2024 15:37:13 提供 Nasdaq GlobeNewswire

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

21 6 2024 06:00:51 提供 Nasdaq GlobeNewswire

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

17 6 2024 06:00:03 提供 Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

03 6 2024 15:30:00 提供 Nasdaq GlobeNewswire

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

23 5 2024 16:00:15 提供 Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

16 5 2024 05:00:45 提供 Nasdaq GlobeNewswire

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

09 5 2024 15:42:04 提供 Nasdaq GlobeNewswire

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

07 5 2024 06:00:11 提供 Nasdaq GlobeNewswire

Arvinas to Present at Upcoming Investor Conferences

02 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

24 4 2024 15:30:38 提供 Nasdaq GlobeNewswire

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

11 4 2024 06:00:49 提供 Nasdaq GlobeNewswire